Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

▤ Summary

Optimi Health has launched two standardized microdose psilocybin finished drug products in 1mg and 2mg doses. The company says the new formats give clinical research organizations consistent, validated dosing for controlled studies. Optimi produces the products in-house at its GMP facility in British Columbia and can supply them to qualified authorized researchers. The launch extends its psilocybin portfolio, which already includes a 5mg formulation used in Australia under an authorized prescriber scheme.

▦ Linked Companies